■关于撒哈拉以南非洲(SSA)糖尿病性黄斑水肿(DMO)的治疗方法的信息很少。这项调查的主要目的是确定在SSA工作的眼科医生对DMO的“现实世界”管理。
■问卷分发给SSA视网膜和眼科协会成员。
■来自24个国家的93名眼科医生参加了会议,其中大多数在尼日利亚工作(51,55%)。大多数是视网膜专家(50,54%)和顾问(67,62%)。62(67%)眼科医生的临床显著黄斑水肿提示治疗,而视力(81,87%)和OCT改变(76,82%)是治疗DMO的更常见原因.治疗包括玻璃体内抗VEGF(91,98%),激光(70,75%),玻璃体内类固醇(57,61%),局部滴剂(52,56%),口服片剂(32,34%)和手术(20,22%)。使用的最常见的玻璃体内抗VEGF药物是贝伐单抗(89,96%)和雷珠单抗(71,76%)。69人(74%)使用玻璃体内注射曲安奈德,局部NSAIDs下降51(55%),和乙酰唑胺片剂由22(24%)眼科医生作为DMO的治疗。
■撒哈拉以南非洲眼科医生通常使用玻璃体内抗VEGF,激光,玻璃体内类固醇,和局部NSAIDs治疗DMO。经济限制和/或无法维持成功的玻璃体内抗VEGF治疗所需的强化方案可能会影响某些治疗选择。
UNASSIGNED: There is minimal information about the availability of treatment for Diabetic macular oedema (DMO) in sub-Saharan Africa (SSA). The principal aim of this survey was to determine the \'real world\' management of DMO amongst ophthalmologists working in SSA.
UNASSIGNED: Questionnaires were distributed to members of retinal and ophthalmological societies in SSA.
UNASSIGNED: Ninety-Three ophthalmologists from 24 countries participated with the majority working in Nigeria (51, 55%). Most were retina specialists (50, 54%) and consultants (67, 62%). Clinically significant macular oedema prompted treatment for 62 (67%) ophthalmologists, whilst visual acuity (81, 87%) and OCT changes (76, 82%) were more common reasons to treat DMO. Treatment included intravitreal anti-VEGF (91, 98%), laser (70, 75%), intravitreal steroid (57, 61%), topical drops (52, 56%), oral tablets (32, 34%) and surgery (20, 22%). The commonest intravitreal anti-VEGF agents used were bevacizumab (89, 96%) and ranibizumab (71, 76%). Intravitreal triamcinolone was used by 69 (74%), topical NSAIDs by 51 (55%), and acetazolamide tablets by 22 (24%) ophthalmologists as a treatment for DMO.
UNASSIGNED: Sub-Saharan African ophthalmologists commonly use intravitreal anti-VEGF, laser, intravitreal steroid, and topical NSAIDs to treat DMO. Economic constraints and/or the inability to maintain the intensive regimen required for successful intravitreal anti-VEGF therapy probably influence some treatment choices.